Assessing the biobehavioral effects of ultramicronized-palmitoylethanolamide monotherapy in autistic adults with different severity levels: a report of two cases
Case seriesHumans
- Design
- Case series
- Subjects
- 2 autistic women with different levels of support need
- Dose used in the study
- 600 mg a day of ultramicronised palmitoylethanolamide, with no other medication
- Duration
- 4 months, with follow-up to 36 weeks
- What was measured
- Distress and mood questionnaires, daily functioning, blood markers of inflammation and endocannabinoid levels
What the authors reported
The authors reported that one patient had improved depressive symptoms and social engagement, with lower inflammatory markers. The other was stable at first, then deteriorated and needed an antipsychotic. No adverse events were reported.
Limits of this study
Two cases with opposite courses. The authors call the report exploratory and note self-assessment bias. The study had no funding, and the product was supplied by its maker, Epitech Group.
Source
doi:10.3389/fpsyt.2024.1463849
Entry checked against the full text at the publisher (Frontiers) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.